Importance of the EP1 receptor in cutaneous UVB-induced inflammation and tumor development

Journal of Investigative Dermatology

Volumn 126, Issue 1, 2006, Pages 205-211

  Tober, Kathleen L ^a   Wilgus, Traci A ^b   Kusewitt, Donna F ^a   Thomas Ahner, Jennifer M ^a   Maruyama, Takayuki ^c   Oberyszyn, Tatiana M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; E PROSTANOID 1 RECEPTOR; ONO 8713; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RISK; DISEASE COURSE; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFLAMMATION; SKIN TUMOR; ULTRAVIOLET B RADIATION;

ANIMALS; CINNAMATES; CYCLOOXYGENASE INHIBITORS; DERMATITIS; FEMALE; KERATINOCYTES; MICE; MICE, INBRED HRS; PYRAZOLES; RECEPTORS, PROSTAGLANDIN E; SKIN; SKIN NEOPLASMS; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 33644784795     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700014     Document Type: Article

References (35)

1. An KP, Athar M, Tang X, Katiyar SK, Russo J, Beech J et al. (2002) Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 76:73-80
2. Athar M, An KP, Morel KD, Kim AL, Aszterbaum M, Longley J et al. (2001) Ultraviolet B (UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem Biophys Res Commun 280:1042-7
3. Buchanan FC, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451-7
4. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J et al. (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19:723-9
5. Couzin J (2004) Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 306:1673-5
6. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA (2003) Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24:945-52
7. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA et al. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin Carcinogenesis. Mol Carcinog 25:231-40
8. Han C, Wu T (2005) Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of epidermal growth factor receptor and AKT. J Biol Chem 280:24053-63
9. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S et al. (2005) Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 26:353-7
10. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H et al. (2001) Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 22:2001-4
11. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24:985-90
12. 2, in adult human epidermis. J Invest Dermatol 124:965-70
13. Konger RL, Scott GA, Landt Y, Ladenson JH, Pentland AP (2002) Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am J Pathol 161:2065-78
14. 51Cr-labeled cells and myeloperoxidase. Inflammation 7:247-55
15. Lupulescu A (1978a) Effect of prostaglandins on skin tumorigenesis. Experientia 34:785-8
16. Lupulescu A (1978b) Enhancement of carcinogenesis by prostaglandins. Nature 272:634-6
17. Nakayama Y, Omote K, Namiki A (2002) Role of prostaglandin receptor EP1 in the spinal dorsal horn in carrageenan-induced inflammatory pain. Anesthesiology 97:1254-62
18. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193-226
19. Negishi M, Sugimoto Y, Ichikawa A (1993) Prostanoid receptors and their biological actions. Prog Lipid Res 32:417-34
20. Negishi M, Sugimoto Y, Ichikawa A (1995) Prostaglandin E receptors. J Lipid Mediat Cell Signal 12:379-91
21. Omote K, Yamamoto H, Kawamata T, Nakayama Y, Namiki A (2002) The effects of intrathecal administration of an antagonist for prostaglandin E receptor subtype EP(1) on mechanical and thermal hyperalgesia in a rat model of postoperative pain. Anesth Analg 95:1708-12, table of contents
22. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS (2002) Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 138:751-5
23. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R (1999) Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20:1939-44
24. Thompson EJ, Gupta A, Vielhauer GA, Regan JW, Bowden GT (2001) The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1. Neoplasia 3:402-10
25. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501
26. Vanchieri C (2004) Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 96:1734-5
27. Vanchieri C (2005) Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. J Natl Cancer Inst 97:552-3
28. Vanderveen EE, Grekin RC, Swanson NA, Kragballe K (1986) Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol 122:407-12
29. Vassiliou E, Sharma V, Jing H, Sheibanie F, Ganea D (2004) Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J Immunol 173:6955-64
30. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59:5093-6
31. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H et al. (2000) Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 156:57-61
32. Watanabe T, Satoh H, Togoh M, Taniguchi S, Hashimoto Y, Kurokawa K (1996) Positive and negative regulation of cell proliferation through prostaglandin receptors in NIH-3T3 cells. J Cell Physiol 169:401-9
33. Wilgus TA, Breza Jr TS, Tober KL, Oberyszyn TM (2004) Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 122:1488-94
34. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM (2003) Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 38:49-58
35. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM (2000) Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostagland Other Lipid Mediat 62:367-84